• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康兔口服和静脉注射D-核糖后的药代动力学评价。

Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits.

作者信息

Alzoubi Karem H, Ismail Zuhair Bani, Al-Essa Mohamed K, Alshogran Osama Y, Abutayeh Reem F, Abu-Baker Nareman

机构信息

Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

Department of Veterinary Clinical Sciences, Faculty of Veterinary Medicine, Jordan University of Science and Technology, Irbid, Jordan.

出版信息

Clin Pharmacol. 2018 Jun 12;10:73-78. doi: 10.2147/CPAA.S167150. eCollection 2018.

DOI:10.2147/CPAA.S167150
PMID:29928149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6003283/
Abstract

INTRODUCTION

This study explored D-ribose pharmacokinetics after intravenous (IV) and oral administration to healthy rabbits.

MATERIALS AND METHODS

D-ribose was administered once as 420 mg/kg (N=4) or 840 mg/kg (N=6) dose intravenously, or as an oral dose of 420 mg/kg (N=3) or 840 mg/kg (N=3). Serum was obtained at various time points, up to 210 minutes after administration. Urine was also collected after IV administration. Pharmacokinetic parameters were determined from drug concentration-time data using Kinetica software.

RESULTS

The findings showed that D-ribose follows a dose-dependent kinetic profile. With doubling the IV dose, AUC was significantly increased by threefold, while the clearance was decreased by 44%. The half-life was 1.7-fold longer at the higher dose. Similar nonsignificant trends were also observed at oral administration. D-ribose was rapidly absorbed (T=36-44 minutes) and rapidly disappeared from plasma (within <140 minutes). Additionally, D-ribose was partially (18-37.5%) recovered from urine.

CONCLUSION

Collectively, D-ribose showed a dose-dependent kinetic profile, where parameters change according to dosing levels. D-ribose clearance seems to follow first-order kinetics at low dose. Thereafter, elimination systems are saturated, and elimination continues in a fast manner. Urine recovery was partial, which could be attributed to the several metabolic pathways that pentose can undergo.

摘要

引言

本研究探讨了健康家兔静脉注射(IV)和口服D-核糖后的药代动力学。

材料与方法

以420mg/kg(N = 4)或840mg/kg(N = 6)的剂量静脉注射D-核糖一次,或以420mg/kg(N = 3)或840mg/kg(N = 3)的剂量口服。在给药后长达210分钟的不同时间点采集血清。静脉注射后也收集尿液。使用Kinetica软件根据药物浓度-时间数据确定药代动力学参数。

结果

研究结果表明,D-核糖呈现剂量依赖性动力学特征。静脉注射剂量加倍时,曲线下面积(AUC)显著增加三倍,而清除率降低44%。高剂量时半衰期延长1.7倍。口服给药时也观察到类似的非显著趋势。D-核糖吸收迅速(T = 36 - 44分钟),并在血浆中迅速消失(<140分钟内)。此外,D-核糖可从尿液中部分回收(18 - 37.5%)。

结论

总体而言,D-核糖呈现剂量依赖性动力学特征,其参数随给药水平而变化。低剂量时D-核糖清除似乎遵循一级动力学。此后,消除系统饱和,消除以快速方式持续进行。尿液回收是部分性的,这可能归因于戊糖可经历的多种代谢途径。

相似文献

1
Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits.健康兔口服和静脉注射D-核糖后的药代动力学评价。
Clin Pharmacol. 2018 Jun 12;10:73-78. doi: 10.2147/CPAA.S167150. eCollection 2018.
2
Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects.健康男性和女性受试者口服溶液后D-核糖的药代动力学、剂量比例性、食物影响及药效学评估。
J Clin Pharmacol. 2014 May;54(5):546-54. doi: 10.1002/jcph.241. Epub 2013 Dec 16.
3
Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.健康男性单次口服托啡肽的药代动力学和物质平衡特征。
Clin Drug Investig. 2024 Jan;44(1):21-33. doi: 10.1007/s40261-023-01322-2. Epub 2023 Nov 28.
4
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.单次静脉推注(0.5 毫克-10 毫克)的药代动力学和药效学,以及测定二肽基肽酶-4 抑制剂利那列汀(BI 1356)在健康男性受试者中的绝对生物利用度。
Clin Pharmacokinet. 2010 Dec;49(12):829-40. doi: 10.2165/11536620-000000000-00000.
5
Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.乙琥胺在猴体内的药代动力学特性。I. 单剂量静脉注射和口服给药。
Epilepsia. 1975 Dec;16(5):705-16. doi: 10.1111/j.1528-1157.1975.tb04755.x.
6
Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.乙二醇的药代动力学。III. 雄性Sprague-Dawley大鼠单次递增静脉注射、口服或经皮给药后的血浆处置及代谢转归
Xenobiotica. 1996 May;26(5):515-39. doi: 10.3109/00498259609046729.
7
Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.1-(2-脱氧-β-D-呋喃核糖基)-2,4-二氟-5-碘苯的剂量依赖性药代动力学:一种潜在的5-碘-2'-脱氧尿苷模拟物
Biopharm Drug Dispos. 2003 Dec;24(9):385-95. doi: 10.1002/bdd.375.
8
Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.在健康受试者中多次给药后新型 Trk 受体正向变构调节剂 ACD856 的安全性、耐受性、药代动力学和定量脑电图评估。
J Prev Alzheimers Dis. 2023;10(4):778-789. doi: 10.14283/jpad.2023.89.
9
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.凡德他尼的药代动力学:三项健康受试者的 I 期研究。
Clin Ther. 2012 Jan;34(1):221-37. doi: 10.1016/j.clinthera.2011.11.011. Epub 2011 Dec 28.
10
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.利拉利汀,一种开发用于治疗 2 型糖尿病的二肽基肽酶-4 抑制剂:在健康成年日本男性受试者中进行的单次和多次递增剂量、随机、双盲、安慰剂对照的 I 期临床试验。
Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

引用本文的文献

1
Sildenafil effect on testosterone-induced prostate hypertrophy and relaxation of urinary bladder neck muscles.西地那非对睾酮诱导的前列腺肥大及膀胱颈部肌肉松弛的影响。
Toxicol Rep. 2025 Jun 30;15:102080. doi: 10.1016/j.toxrep.2025.102080. eCollection 2025 Dec.
2
D-ribose metabolic disorder and diabetes mellitus.D-核糖代谢紊乱与糖尿病。
Mol Biol Rep. 2024 Jan 28;51(1):220. doi: 10.1007/s11033-023-09076-y.
3
Ribose Intake as Food Integrator: Is It a Really Convenient Practice?核糖摄取作为食物整合剂:这真的是一种方便的做法吗?

本文引用的文献

1
D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study.D-核糖对射血分数保留及舒张功能障碍的心力衰竭患者的作用:一项初步研究。
Ther Adv Cardiovasc Dis. 2015 Jun;9(3):56-65. doi: 10.1177/1753944715572752. Epub 2015 Feb 19.
2
Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects.健康男性和女性受试者口服溶液后D-核糖的药代动力学、剂量比例性、食物影响及药效学评估。
J Clin Pharmacol. 2014 May;54(5):546-54. doi: 10.1002/jcph.241. Epub 2013 Dec 16.
3
D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice.
Biomolecules. 2022 Nov 29;12(12):1775. doi: 10.3390/biom12121775.
D-核糖通过抑制小鼠肾脏炎症改善顺铂诱导的肾毒性。
Tohoku J Exp Med. 2013 Mar;229(3):195-201. doi: 10.1620/tjem.229.195.
4
Evaluation of α-D-ribofuranose (D-ribose) toxicity after intravenous administration to rabbits.静脉给予兔α-D-呋喃核糖(D-核糖)后的毒性评价。
Hum Exp Toxicol. 2012 Aug;31(8):820-9. doi: 10.1177/0960327111432505. Epub 2012 Jan 16.
5
Protective action of D-ribose against renal injury caused by ischemia and reperfusion in rats with transient hyperglycemia.D-核糖对短暂性高血糖大鼠肾缺血再灌注损伤的保护作用。
Tohoku J Exp Med. 2009 Nov;219(3):215-22. doi: 10.1620/tjem.219.215.
6
A photometric method for the determination of free pentoses in animal tissues.一种测定动物组织中游离戊糖的光度法。
J Biol Chem. 1948 Apr;173(2):507-12.
7
The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study.D-核糖在慢性疲劳综合征和纤维肌痛中的应用:一项初步研究。
J Altern Complement Med. 2006 Nov;12(9):857-62. doi: 10.1089/acm.2006.12.857.
8
Metabolism of d-ribose in diabetes mellitus.糖尿病中d-核糖的代谢
Diabetes. 1959 Nov-Dec;8:455-8. doi: 10.2337/diab.8.6.455.
9
The metabolism of D-ribose in man.人体内D-核糖的代谢
J Clin Invest. 1958 May;37(5):719-35. doi: 10.1172/JCI103658.
10
Studies of ribose metabolism. III. The pathway of ribose carbon conversion to glucose in man.核糖代谢的研究。III. 人体中核糖碳转化为葡萄糖的途径。
J Clin Invest. 1958 May;37(5):651-4. doi: 10.1172/JCI103649.